Connect with us

News

Sarwa Helps UAE Residents Easily Invest In Global Stocks

Published

on

sarwa now helps uae residents invest in global stocks

Sarwa, the UAE-based online investment platform that is democratizing investing in the region, allows anyone to invest small amounts of money in global markets making investing simple and affordable for all investors in the Middle East.

Thanks to modern technology, lucrative investment opportunities are no longer available only to individuals with traditional access to stock markets. These days, there are many apps that let inexperienced and seasoned investors alike sit on a couch and invest their hard-earned money using nothing but a smartphone, and Sarwa is one of them.

The investment platform launched in February 2018 after raising over $1.3 million from regional and global investors during a pre-Series A. “We’re so excited to close this round with the top VCs regionally and internationally that are backing Sarwa in its growth,” said Mark Chahwan, CEO and co-founder of Sarwa, at the time.

sawra online investment platform founders

Sarwa Founders

Fast-forward to today, and Sarwa has over 25,000 registered users, who use it to invest in international stock markets through a range of class assets. Sarwa caters to everyone regardless of their net worth: the platform has high net worth individuals, mass affluent as well as small retail investors. The same users will soon be able to trade with global shares without paying any commission on their trades.

What separates Sarwa from other investment platforms that are licensed to operate in UAE, such as Wealthface or Stashaway, is its AI-driven hybrid nature and exceptional customer support. The app platform uses artificial intelligence to recommend a specific investment portfolio based on each investor’s preferences and investment priorities while also providing their client base with access to humans when needed.

Also Read: Anghami Becomes First Arab Tech Company To List On NASDAQ

“When you start investing with Sarwa, we assess your risk profile and recommend a diversified portfolio that reflects it,” explains Chahwan. “If you are a short-term investor, then your portfolio will inherently be less risky. If you are in a portfolio that has more exposure to stocks, which is considered more growth and more risk, then you are in it for the long-term and the short-term (even if it is a couple of years) won’t have an impact on your long-term strategy.”

In its beta form, access to global stock trading will be provided exclusively to Sarwa Invest customers, but other Sarwa users can enter a waiting list to join when the full product is launched.

Advertisement

📢 Get Exclusive Monthly Articles, Updates & Tech Tips Right In Your Inbox!

JOIN 17K+ SUBSCRIBERS

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

News

Orchid Plans To Find Out What’s Wrong With You Before You’re Born

According to CEO Noor Siddiqui, the company isn’t on a mission to make designer babies, but aims to beat genetic odds and relieve suffering.

Published

on

startup orchid plans to find out what's wrong with you before you're born
Orchid

Each day, around 400,000 babies are welcomed into the world. However, among those, a growing number will experience some kind of birth defect or inherited disease.

Noor Siddiqui, CEO of Orchid, hopes to “mitigate” unpleasant genetic surprises using genome sequencing technology to reveal a wealth of genetic information on which newborns will grow into healthy adults.

Until 2019, IVF specialists had access to under 1% of the human genome. The tests, called PGT-A and PGT-M, scanned a mere 1,000 data points in a genome comprising around 3 billion bases, offering a very limited dataset compared to the technology used by Orchid.

“Our chromosomes are like chapters in a book that make up the table of contents.” Explained Siddiqui. “[PGT-A and PGT-M tests] only examine the table of contents, whereas what Orchid is doing is like a spellcheck on the entire book.” Orchid’s genome sampling technology assesses “100 times the data, covering many more conditions.” In essence, an Orchid report covers three categories of common genetic issues: monogenic disorders, polygenic conditions, and de-novo mutations.

Also Read: Advancing MENA Health Through AI Vascular Age Analysis

Orchid’s technology raises many questions. Aside from the obvious ethical concerns, data privacy is the most obvious potential issue with the tests. Noor Siddiqui is keen to alleviate any concerns: “No data at Orchid is ever sold to any third parties. Parents are in complete control of their data. If they want to delete the data, we’re happy to delete it off of our servers. If they want to export the data, they can export the data. And if they want us to re-analyze the data, we can re-analyze the data”.

Compared to a lifetime of medical bills, gene therapy, and suffering, Orchid’s genome screening report has the potential to change the future lives of thousands of newborns worldwide.

Continue Reading

#Trending